Literature DB >> 12769710

Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.

Marc Venet1, David End, Patrick Angibaud.   

Abstract

R115777 (R)-6-amino[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone is a potent and selective inhibitor of farnesyl protein transferase with significant antitumor effects in vivo subsequent to oral administration in mice. Taking its roots into Janssen's ketoconazole and retinoic acid catabolism programs, our interest into Ras prenylation process led us stepwise to identify the key structural features of R115777. Methodology, structure activity relationships, and pharmacology will be presented. R115777 is currently in phase III clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769710     DOI: 10.2174/1568026033452050

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  11 in total

1.  Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.

Authors:  Frederick S Buckner; Maria Terezinha Bahia; Praveen Kumar Suryadevara; Karen L White; David M Shackleford; Naveen Kumar Chennamaneni; Matthew A Hulverson; Joy U Laydbak; Eric Chatelain; Ivan Scandale; Christophe L M J Verlinde; Susan A Charman; Galina I Lepesheva; Michael H Gelb
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

2.  Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Authors:  Thomas E Witzig; Hui Tang; Ivana N M Micallef; Stephen M Ansell; Brian K Link; David J Inwards; Luis F Porrata; Patrick B Johnston; Joseph P Colgan; Svetomir N Markovic; Grzegorz S Nowakowski; Carrie A Thompson; Cristine Allmer; Matthew J Maurer; Mamta Gupta; George Weiner; Ray Hohl; Paul J Kurtin; Husheng Ding; David Loegering; Paula Schneider; Kevin Peterson; Thomas M Habermann; Scott H Kaufmann
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

3.  Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.

Authors:  James M Kraus; Hari Babu Tatipaka; Sarah A McGuffin; Naveen Kumar Chennamaneni; Mandana Karimi; Jenifer Arif; Christophe L M J Verlinde; Frederick S Buckner; Michael H Gelb
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

4.  Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.

Authors:  Steven Fletcher; Erin Pusateri Keaney; Christopher G Cummings; Michelle A Blaskovich; Michael A Hast; Matthew P Glenn; Sung-Youn Chang; Cynthia J Bucher; Ryan J Floyd; William P Katt; Michael H Gelb; Wesley C Van Voorhis; Lorena S Beese; Said M Sebti; Andrew D Hamilton
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

5.  Rational modification of a candidate cancer drug for use against Chagas disease.

Authors:  James M Kraus; Christophe L M J Verlinde; Mandana Karimi; Galina I Lepesheva; Michael H Gelb; Frederick S Buckner
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

Review 6.  Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.

Authors:  Angela Jeong; Kiall Francis Suazo; W Gibson Wood; Mark D Distefano; Ling Li
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-06       Impact factor: 8.250

Review 7.  Farnesyltransferase inhibitors in myelodysplastic syndrome.

Authors:  E J Feldman
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 4.213

8.  Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.

Authors:  Ruth Alonso-Alonso; Rufino Mondéjar; Nerea Martínez; Nuria García-Diaz; Cristina Pérez; David Merino; Marta Rodríguez; Anna Esteve-Codina; Berta Fuste; Marta Gut; Francis Burrows; Catherine Scholz; Jose Pedro Vaqué; Antonio Gualberto; Miguel Ángel Piris
Journal:  Sci Rep       Date:  2020-04-21       Impact factor: 4.379

9.  Tipifarnib in the treatment of acute myeloid leukemia.

Authors:  Xavier Thomas; Mohamed Elhamri
Journal:  Biologics       Date:  2007-12

10.  Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

Authors:  A Sparreboom; D F S Kehrer; R H J Mathijssen; R Xie; M J A de Jonge; P de Bruijn; A S T Planting; F A L M Eskens; C Verheij; G de Heus; A Klaren; S Zhang; T Verhaeghe; P A Palmer; J Verweij
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.